Filters
cris logo
-
New search Filters
Select from list
Displayed from Show more
You have reached the maximum number of displayed search results.
All results displayed
No results are available for the search performed
Displayed from
You have reached the maximum number of displayed search results.
All results displayed
Loading results
Obtaining statistical data

Projects / Programmes source: ARIS

Zdravljenje malignih solidnih tumorjev z interferonom alfa (Slovene)

Edit
Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B007  Biomedical sciences  Medicine (human and vertebrates) 
B200  Biomedical sciences  Cytology, oncology, cancerology 
Keywords
interferon alfa, chemoimmunotherapy, immunopotentiation, NK cells
Evaluation (rules)
source: COBISS
Evaluation of bibliographic research performance indicators according to ARIS methodology
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Researchers (8)
no. Code Name and surname Research area Role Period No. of publications
1.  00702  PhD Marjan Budihna  Oncology  Researcher  1998 - 2001  0 
2.  14932  MSc Zvezdana Hlebanja  Oncology  Researcher  1998 - 2001  0 
3.  05318  PhD Berta Jereb  Oncology  Researcher  2000 - 2001  0 
4.  03171  PhD Aleksandra Markovič-Predan  Medical sciences  Researcher  1998 - 2001  0 
5.  13541  PhD Janja Ocvirk  Oncology  Researcher  1998 - 2001  0 
6.  11949  PhD Borut Štabuc  Oncology  Head  2000 - 2001  0 
7.  12686  PhD Neva Volk  Medical sciences  Researcher  1998 - 2001  0 
8.  07195  PhD Ivan Vrhovec  Oncology  Researcher  1998 - 2001  0 
Organisations (1)
no. Code Research organisation City Registration number No. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  0 
Abstract
The aim of study is to establish the effect of addition of IFN-alfa to cisplatin, vinblastine, 5-fluorouracil or paclitaxel on survival of patients with metastatic melanoma, renal cancer, lung cancer and head and neck cancer. Combined treatment effect will be evaluaated by clinical parameters (response rate, duration of survival and time to progression) and immunologically (determination of lymphocytes CD4, Th1, Th2, CD8, NK cells and activity of NK cells).
Confirmation required
Views history
Favourite